Accéder au contenu
Merck

Direct reprogramming of cardiomyocytes into cardiac Purkinje-like cells.

iScience (2022-11-18)
Nicole Prodan, Faheem Ershad, Arfaxad Reyes-Alcaraz, Luge Li, Brandon Mistretta, Lei Gonzalez, Zhoulyu Rao, Cunjiang Yu, Preethi H Gunaratne, Na Li, Robert J Schwartz, Bradley K McConnell
RÉSUMÉ

Currently, there are no treatments that ameliorate cardiac cell death, the underlying basis of cardiovascular disease. An unexplored cell type in cardiac regeneration is cardiac Purkinje cells; specialized cells from the cardiac conduction system (CCS) responsible for propagating electrical signals. Purkinje cells have tremendous potential as a regenerative treatment because they may intrinsically integrate with the CCS of a recipient myocardium, resulting in more efficient electrical conduction in diseased hearts. This study is the first to demonstrate an effective protocol for the direct reprogramming of human cardiomyocytes into cardiac Purkinje-like cells using small molecules. The cells generated were genetically and functionally similar to native cardiac Purkinje cells, where expression of key cardiac Purkinje genes such as CNTN2, ETV1, PCP4, IRX3, SCN5a, HCN2 and the conduction of electrical signals with increased velocity was observed. This study may help to advance the quest to finding an optimized cell therapy for heart regeneration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Fibrinogène from bovine plasma, Type I-S, 65-85% protein (≥75% of protein is clottable)
Sigma-Aldrich
Papain from Carica papaya, solution, light brown, ≥10 U/mg protein (~25 mg/ml)
Sigma-Aldrich
TGF-β RI Kinase Inhibitor VI, SB431542, InSolution, ≥97%